genOway
Develops genetically engineered preclinical models for biopharma and academic research.
ALGEN | PA
Overview
Corporate Details
- ISIN(s):
- FR0004053510
- LEI:
- 969500HMHUPR3KYXUT19
- Country:
- France
- Address:
- 31 RUE SAINT JEAN DE DIEU, 69007 LYON
- Website:
- https://www.genoway.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
genOway is a global biotechnology company founded in 1999 that specializes in developing genetically engineered preclinical models. The company provides a range of solutions, including custom-designed and catalog mouse, rat, and cell line models, to the biopharmaceutical industry and academic institutions. These models are engineered for high predictability and are utilized in fundamental and preclinical research for applications such as target validation, compound efficacy assessment, and safety studies. genOway's core mission is to bridge the gap between preclinical findings and clinical success by offering advanced, reliable research tools and collaborative scientific expertise.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for genOway and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-27 17:55 |
Earnings Release
Résultats annuels 2024 - genOway accélère le déploiement de son plan stratégiqu…
|
French | 223.0 KB | |
| 2025-01-20 18:00 |
Earnings Release
Croissance solide de +10% de l'activité en 2024 à 22,1 M EUR
|
French | 194.7 KB | |
| 2024-11-04 18:00 |
Regulatory News Service
Lutte contre l'obésité et les maladies métaboliques : les modèles humanisés de …
|
French | 130.1 KB | |
| 2024-09-23 18:00 |
Earnings Release
Résultats semestriels 2024 conformes avec les objectifs du nouveau plan stratég…
|
French | 207.7 KB | |
| 2024-07-18 18:00 |
Earnings Release
Un 1er semestre 2024 en croissance de +15%, de bon augure en pleine mise en oeu…
|
French | 176.4 KB | |
| 2024-07-04 18:00 |
Business and Financial Review
Bilan semestriel du contrat de liquidité
|
French | 355.0 KB | |
| 2024-06-25 17:55 |
Regulatory News Service
Solide démarrage du développement de la coentreprise genOway Shanghai en Chine
|
French | 198.0 KB | |
| 2024-03-28 18:00 |
Regulatory News Service
Organisation d'une visioconférence destinée aux investisseurs individuels
|
French | 128.0 KB | |
| 2024-03-26 17:45 |
Earnings Release
Résultats annuels 2023 : genOway poursuit sur sa lancée avec une croissance de …
|
French | 219.5 KB | |
| 2024-02-09 11:00 |
Regulatory News Service
genOway fait son entrée au palmarès 2024 des 500 ' Champions de la croissance '
|
French | 129.5 KB | |
| 2024-01-22 08:00 |
Regulatory News Service
genOway participe à la 1ère édition du Retail Day organisée par Euroland Corpor…
|
French | 125.7 KB | |
| 2024-01-16 18:05 |
Board/Management Information
genOway dévoile Route 50+, son nouveau plan stratégique visant à bâtir un leade…
|
French | 198.9 KB | |
| 2024-01-16 18:00 |
Earnings Release
genOway dépasse le seuil des 20 M EUR de chiffre d'affaires en 2023, porté par …
|
French | 176.3 KB | |
| 2023-11-22 18:00 |
Report Publication Announcement
Initiation de la couverture du titre genOway par Euroland Corporate
|
French | 100.2 KB | |
| 2023-10-17 18:00 |
M&A Activity
genOway crée une coentreprise à Shanghai avec pour objectif de devenir le parte…
|
French | 141.9 KB |
Automate Your Workflow. Get a real-time feed of all genOway filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for genOway via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-17 | N/A | Other | Sell | 1,700 | 8,160.00 EUR |
| 2023-12-15 | N/A | Other | Sell | 5,000 | 22,000.00 EUR |
| 2023-11-23 | N/A | Other | Sell | 500 | 2,100.00 EUR |
| 2023-10-23 | N/A | Other | Sell | 100 | 390.00 EUR |
| 2023-09-25 | N/A | Other | Buy | 5,000 | 20,000.00 EUR |
| 2023-05-04 | N/A | Other | Buy | 60,000 | 222,000.00 EUR |
| 2023-05-02 | N/A | Other | Sell | 20,000 | 74,000.00 EUR |
